LightNews LightNews
rautoupe.bsky.social
@rautoupe.bsky.social
51 followers 43 following 6 posts
Posts Replies Media Videos
Reposted
kvvanten.bsky.social
In the (early) pathophysiology of MASLD the LSEC and microvascular alterations are key. Lanifibranor improves LSEC capillarisation and dysfunction! tinyurl.com/x37637j4
#AntwerpHepatology #AntwerpHypothesis @rautoupe.bsky.social @svenfrancque.bsky.social
May 13, 2025 at 7:41 AM
Reposted
decision4liver.bsky.social
Is the etiological work-up of #PSVD a one-size-fits-all?

DECISION consortium member Lucile Moga from APHP takes part in EASL/ VALDIG's session on "Do's and Don'ts in the management of Porto-Sinusoidal Vascular Disease".

#EASLCongress #EASL2025 #LiverResearch
@easlnews.bsky.social
May 10, 2025 at 7:00 AM
Reposted
mattiasmandorfer.bsky.social
📢 First @easlnews.bsky.social CPG on surgery in cirrhosis presented today together with the one on TIPS!
🤝 See you at 10:30 Erlinger Room!
@bavenocoop.bsky.social #LiverSky
jhepatology.bsky.social Journal of Hepatology @jhepatology.bsky.social · May 10
🆕CPG in press❕

EASL Clinical Practice Guidelines on extrahepatic abdominal surgery in patients with cirrhosis and advanced chronic liver disease

Find it here👉https://bit.ly/3GM9EEB

#LiverSky
@easlnews.bsky.social
May 10, 2025 at 6:16 AM
Reposted
decision4liver.bsky.social
Estefania Huergo presents methylation data in AD patients, selected as best Young Investigator abstract in Basic Science at #EASL2025 - Congrats! 🎉
@navarrabiomed.bsky.social
@easlnews.bsky.social
#Epigenetics #LiverResearch
May 10, 2025 at 8:42 AM
Reposted
decision4liver.bsky.social
Back in the Abstract Session: Theresa Wirtz presents her scRNA-seq work on monocyte subsets and ACLF risk.

@rwth.bsky.social
@brunslab.bsky.social
@easlnews.bsky.social

#Cirrhosis #ACLF #EASL2025"
May 10, 2025 at 8:58 AM
Reposted
decision4liver.bsky.social
❤️ Cardiac performance is impaired in patients with proven alcohol-related hepatitis and predicts 3-month mortality in this patient population

#POSTER SAT-503-YI by Pierre-Emmanuel Rautou (@inserm.fr, APHP, EF CLIF)

📅 Presented at the #EASLCongress | #EASL2025
@easlnews.bsky.social
May 10, 2025 at 10:07 AM
Reposted
decision4liver.bsky.social
How do you build&lead a successful research team?
The next generation of PIs learned straight from the best in today's workshop “How to Start a Research Group: From Postdoc to PI" as @rautoupe.bsky.social shared practical insights on building&maintaining a high-performing team.
@inserm.fr #EASL2025
May 9, 2025 at 4:33 PM
Reposted
decision4liver.bsky.social
Greetings from the DECISION Investigator Meeting at #EASL2025: Study updates and collaborative discussions with Paolo Caraceni & @rautoupe.bsky.social

#ClinicalTrials #cirrhosis
May 9, 2025 at 9:55 AM
Reposted
decision4liver.bsky.social
Good morning!
DECISION coordinator Pierre-Emmanuel Rautou just started the early morning abstract session on #cirrhosis at the #EASLCongress in Amsterdam. You can still join in the Benhamou Room until 09.45am! @easlnews.bsky.social
May 9, 2025 at 6:42 AM
Reposted
decision4liver.bsky.social
Next at the DECISION Networking Session at #EASL2025, Theresa Wirtz (UKA) presents scRNA-seq data showing a monocyte subset linked to ACLF risk.
Fascinating translational science in action!
@brunslab.bsky.social ky.social @easlnews.bsky.social ky.social

#scRNAseq #ACLF
May 9, 2025 at 8:09 AM
Reposted
decision4liver.bsky.social
Lastly at DECISION's Networking Session, Richard Moreau shares new data: high-throughput omics reveals biomarkers for infection & poor outcomes in cirrhosis.
@inserm.fr @easlnews.bsky.social sky.social

#Metabolomics #Cytokinomics #EASL2025
May 9, 2025 at 8:23 AM
Reposted
rautoupe.bsky.social
📢📢 looking for a co-founder (CEO) for an early stage medtech startup‼️

Our goal: bring extracellular vesicles from the lab to the bedside of patients with chronic liver disease.🧪

Find the offer here: www.lesdeeptech.fr/tandem/41693...
March 15, 2025 at 2:03 PM
Reposted
decision4liver.bsky.social
Kicking off our #EASL2025 Networking Session with an intro to the DECISION project by coordinator Pierre-Emmanuel Rautou - Let’s talk systems medicine, cirrhosis, and precision care! @rautoupe.bsky.social pe.bsky.social @easlnews.bsky.social ky.social #LiverDisease
May 9, 2025 at 8:02 AM
rautoupe.bsky.social
Interested in vascular liver diseases and more broadly in liver and vessels?
▶️Join the COST Action EURO-VALDI-NET: www.cost.eu/actions/CA23...

Eligibility criteria there: www.cost.eu/am-i-eligible/
European vascular liver diseases network
Vascular liver diseases are a heterogeneous group of rare disorders characterized by an impaired vascular flow in the splanchnic and/or intrahepatic vasculature. They mainly include recent portal...
www.cost.eu
March 21, 2025 at 7:01 AM
rautoupe.bsky.social
📢📢 looking for a co-founder (CEO) for an early stage medtech startup‼️

Our goal: bring extracellular vesicles from the lab to the bedside of patients with chronic liver disease.🧪

Find the offer here: www.lesdeeptech.fr/tandem/41693...
March 15, 2025 at 2:03 PM
rautoupe.bsky.social
📢📢 Analysis of 249 patients with MASLD and of 2 rat models:
⚠️Liver endothelial cell (LSEC) capillarisation appears before MASH onset
❌LSEC capillarisation progresses with liver fibrosis and inflammation
✅Lanifibranor improves LSEC function

authors.elsevier.com/sd/article/S...
February 22, 2025 at 8:08 PM
rautoupe.bsky.social
Tips for managing invasive procedures in patients with cirrhosis 🩸🩸:
➡️What limits of laboratory values❓
➡️How to risk stratify procedures❓
➡️When to stop and restart anticoagulants and antiplatelet agents❓
Find this and more there:
doi.org/10.3350/cmh....
February 18, 2025 at 9:11 PM
rautoupe.bsky.social
📢📢Interested in vascular liver diseases❓
Check the opportunities for:
✅Short Term Scientific Mission 🧳
Deadline Feb 21
✅Conference Grants
Deadline March 14

➡️ more details there
www.valdig.eu/cost-action-...
February 8, 2025 at 8:48 PM
Reposted
ruicastrohd.bsky.social
@rautoupe.bsky.social provides an update on endothelium-platelet interactions in SLD:

🎯 LSEC capillarisation increases with liver fibrosis in MASLD
🎯 Aspirin improves MASLD
🎯 Likely by inhibiting platelet accumulation and/or platelet EV release

@easlnews.bsky.social #SLDSummit
January 24, 2025 at 6:36 PM
Reposted
livertrack.bsky.social
➡️ Following by Marion Biquard's speech on the measurement of the EV proteins 🧬

@rautoupe.bsky.social @ap-hp.bsky.social @institutcurie.bsky.social
January 20, 2025 at 9:53 PM
Reposted
livertrack.bsky.social
🔬The proteomic aspect of the LIVER-TRACK project was presented by Prof. Laure Elkrief 🩺

@rautoupe.bsky.social @cri1149.bsky.social
January 20, 2025 at 9:53 PM
Reposted
livertrack.bsky.social
🧪The Curie Core Tech team is an essential partner for the proteomics aspect of the RHU LIVER-TRACK project. We are very pleased with their contribution alongside us🙏

@institutcurie.bsky.social @ap-hp.bsky.social @rautoupe.bsky.social
January 20, 2025 at 9:53 PM
Reposted
livertrack.bsky.social
➡️Catlado Schietroma from Abbelight, a partner in the RHU LIVER-TRACK project,has presented the progress of their work in WP3 of LIVER-TRACK🧬🧬

@rautoupe.bsky.social
January 20, 2025 at 9:53 PM
Reposted
livertrack.bsky.social
🙏A big thank you to Prof. Cedric Laouenan🩺 for his insightful presentation during the Livertrack General Assembly! Your contribution was highly appreciated👌

#Livertrack #GeneralAssembly #Gratitude

@hopitalbichat.bsky.social @rautoupe.bsky.social @ap-hp.bsky.social
January 20, 2025 at 9:53 PM
Reposted
livertrack.bsky.social
▶️ A real pleasure to hear Professor Durand Zaleski discuss the medical-economic costs and what will be done in the RHU LIVER-TRACK project 💸💸
Looking forward to the upcoming developments!

#LiverTrack #MedicalEconomics #RHU

@ap-hp.bsky.social @rautoupe.bsky.social @hoteldieuparis.bsky.social
January 20, 2025 at 9:53 PM